# Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes

> **NCT01686945** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 107 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2
- Healthy

## Interventions

- **DRUG:** semaglutide
- **DRUG:** semaglutide
- **DRUG:** semaglutide
- **DRUG:** placebo
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01686945
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-19
- **Primary completion:** 2013-04-08
- **Final completion:** 2013-04-08
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2019-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01686945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01686945, "Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01686945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*